(Q34336925)

1 August 2017

title

Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial (English)

1 reference

1 August 2017

main subject

phase III clinical trial

0 references

0 references

0 references

Mark T Brown

1

1 reference

1 August 2017

Frederick T Murphy

2

1 reference

1 August 2017

David M Radin

3

1 reference

1 August 2017

Isabelle Davignon

4

1 reference

1 August 2017

Michael D Smith

5

1 reference

1 August 2017

Christine R West

6

1 reference

1 August 2017

publication date

1 July 2013

1 reference

1 August 2017

published in

Arthritis & Rheumatology

1 reference

1 August 2017

volume

65

1 reference

1 August 2017

issue

7

1 reference

1 August 2017

page(s)

1795-1803

1 reference

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II

1 August 2017

cites work

1 reference

OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines

21 January 2018

1 reference

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

21 January 2018

1 reference

Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity.

21 January 2018

1 reference

Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors

21 January 2018

1 reference

NGF as a mediator of inflammatory pain.

21 January 2018

1 reference

The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors

21 January 2018

1 reference

The many functions of nerve growth factor: multiple actions on nociceptors

21 January 2018

1 reference

The nerve growth factor receptor: a multicomponent system that mediates the actions of the neurotrophin family of proteins

21 January 2018

1 reference

Nerve growth factor: two receptors, multiple functions

21 January 2018

1 reference

Unraveling the story of NGF-mediated sensitization of nociceptive sensory neurons: ON or OFF the Trks?

21 January 2018

1 reference

Novel class of pain drugs based on antagonism of NGF.

21 January 2018

1 reference

Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee

21 January 2018

1 reference

Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial.

21 January 2018

1 reference

The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip.

21 January 2018

1 reference

OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited.

21 January 2018

1 reference

Clinically relevant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteoarthritis

21 January 2018

1 reference

Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.37950

1 reference

1 August 2017

1 reference